Qiagen Sees Brighter Reimbursement Outlook For Companion Diagnostics
This article was originally published in The Gray Sheet
Executive Summary
Personalized health care remains an important growth driver for the diagnostics developer, which is juggling some 15 companion diagnostics projects. The reimbursement landscape for FDA-approved tests is improving, Qiagen says.